.png){kind=icon}
.png){kind=icon}
Return
Beta-defensin index: A functional biomarker for oral cancer detection
.png){kind=icon}
OA
AI
DOI：10.1016/j.xcrm.2024.101447.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
There is an unmet clinical need for a non-invasive and cost-effective test for oral squamous cell carcinoma (OSCC) that informs clinicians when a biopsy is warranted. Human beta-defensin 3 (hBD-3), an epithelial cell -derived anti -microbial peptide, is pro-tumorigenic and overexpressed in early -stage OSCC compared to hBD-2. We validate this expression dichotomy in carcinoma in situ and OSCC lesions using immunofluorescence microscopy and flow cytometry. The proportion of hBD-3/hBD-2 levels in non -invasively collected lesional cells compared to contralateral normal cells, obtained by ELISA, generates the beta-defensin index (BDI). Proof -of -principle and blinded discovery studies demonstrate that BDI discriminates OSCC from benign lesions. A multi -center validation study shows sensitivity and specificity values of 98.2% (95% confidence interval [CI] 90.3-99.9) and 82.6% (95% CI 68.6-92.2), respectively. A proof -of -principle study shows that BDI is adaptable to a point -of -care assay using microfluidics. We propose that BDI may fulfill a major unmet need in low -socioeconomic countries where pathology services are lacking.
Keywords:
SQUAMOUS-CELL CARCINOMA
GROWTH-FACTOR RECEPTOR
HUMAN BETA-DEFENSIN-1
POTENTIAL APPLICATIONS
TUMOR-SUPPRESSOR
GENE-EXPRESSION
MESSENGER-RNA
CAVITY CANCER
HEAD
BRUSH
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.6
Papers:
2.2K
Citations:
8.9K
Organization
View more organizations